Skip to main content
HR 4692 118th Congress House Health Civil actions and liability Drug safety, medical device, and laboratory regulation Prescription drugs

Increasing Prescription Drug Competition Act

Introduced: July 17, 2023 Introduced by: Slotkin, Elissa Democratic · Michigan See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 21, 2023
Referred to the Subcommittee on Health.
Jul 17, 2023
Introduced in House
Jul 17, 2023
Referred to the House Committee on Energy and Commerce.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Increasing Prescription Drug Competition Act

This bill provides that certifications in generic drug applications of certain patents involved in Risk Evaluation and Mitigation Strategy (REMS) programs have no effect upon the drug's approval. (The Food and Drug Administration sometimes requires a REMS program for certain drugs with safety risks, which may include restrictions on a drug's distribution through elements to ensure safe use (ETASU), such as special requirements for pharmacies that dispense the drug.)

Specifically, certifications in generic drug applications with respect to patents that involve an ETASU for REMS requirements have no effect on the effective date of the drug's approval, notwithstanding any other provisions that allow for a stay of approval pending litigation outcomes (i.e., 30-month stay).

The bill also specifies that in a civil action alleging patent infringement with respect to REMS requirements, the sponsor of the approved brand-name drug may only seek damages from (rather than an injunction against) the generic drug applicant.

What's happening now July 21, 2023

Referred to the Subcommittee on Health.

 Related & companion bills 1
  • S 574 Related bill Increasing Prescription Drug Competition Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Lobbying activity 6

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 4692: Increasing Prescription Drug Competition Act. 118th Congress. Open America. https://openamerica.io/bill/118-HR-4692/
MLA
"H.R. 4692: Increasing Prescription Drug Competition Act." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-HR-4692/.
Bluebook (legal)
H.R. 4692, 118th Cong. (2026), https://openamerica.io/bill/118-HR-4692/.
Markdown link
[H.R. 4692: Increasing Prescription Drug Competition Act](https://openamerica.io/bill/118-HR-4692/)
Report a problem